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Intrahepatic cholangiocarcinoma (ICC) is rising in incidence
owing to improved recognition and a truly increased rate of
the disease. Therefore, understanding the disease, its natural
history and the impact of resection is critical for surgeons. The
authors have succinctly reviewed the role of surgical interven-
tion and acknowledged the controversies and significant
remaining questions1. Resection is indicated for a single
tumour without nodal metastases or other sites of extrahepatic
disease. This is based on long-term survival figures and, most
importantly, the potential for a cure. There is no controversy
on this point. Furthermore, there is no controversy about the
conclusion that surgery is not indicated in patients with distant
extrahepatic metastatic disease. Surgery does not appear to
impact the short survival seen in such patients and could only
be considered palliative and non-curative.
The review dedicates a significant amount of space to the
discussion of multi-focal liver disease and satellitosis. While
these two entities are difficult to distinguish from each other
and remain poorly defined, they are both poor prognostic
signs. Although well-established definitions are lacking, and
most studies do not distinguish between the two, the presence
of satellite tumours and distant multi-focal hepatic disease are
likely a spectrum of the same biologic phenomenon – meta-
static disease. It is possible that multi-focal tumours could be
representative of simultaneous primary tumours but, to our
knowledge, this has never been demonstrated in ICC. While
rare long-term survival is seen after resection of multi-focal
disease, one must always be cognizant of the rare long-term
survival that can be seen with almost any advanced malignancy
associated with almost any therapy. It is likely that these long-
term survivors are patients with indolent cancer who are not
cured. Survival statistics demonstrate that nearly all patients
with multi-focal disease will succumb to their disease, and
most will die quickly. Large case series have demonstrated that
multi-focal disease and satellitosis (usually grouped together)
are signs of advanced disease, and surgery is rarely associated
with durable long-term disease-free survival2–4. Surgery for
patients with multi-focal disease should only be considered in
unusual situations, and preferably within a study protocol.
Whether there is a difference between satellites and multi-focal
disease remains to be determined.
The same can be said of regional nodal metastases. Most ser-
ies analysing outcome after a resection in the setting of nodal
metastases demonstrate a similar poor long-term survival.
These series are likely reporting on gross nodal disease as a
routine lymphadenectomy is not uniformly practiced. While
long-term survival with resection for nodal disease is reported,
it is uncommon, and the majority of patients perform poorly
and die quickly after surgery. It is likely that the reported
long-term survivors are patients with occult microscopic nodal
disease (as mentioned in the review) although this issue is typi-
cally not addressed in studies. Patients who present with radio-
logically gross nodal disease, even if localized to the porta
hepatis, have a poor prognosis and upfront resection probably
should be avoided. Given the very high risk of early recurrence
after resection, re-assessment after a course of neoadjuvant sys-
temic chemotherapy is a strategy to consider. A routine lym-
phadenectomy is strongly recommended by the authors as this
confers better staging. We find it interesting that the prognos-
tic value of lymph node metastases in patients with resected
ICC has been known for a long time but only recently has the
issue of routine staging lymphadenectomy been raised. The
reader should consider why this is suddenly such an important
issue for ICC. In an opposite trend, the value of a lymphaden-
ectomy in patients with melanoma and breast cancer is now
being questioned. Despite decades of research, a standard lym-
phadenectomy for solid tumours has not been shown to
improve survival and probably should only be used for staging
information – preferably with specific treatment strategies
based on the results. Further, in a very similar clinical situation
(yield of positive nodes and prognostic value) of resectable
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metastatic colorectal cancer to the liver, a lymphadenectomy is
not routinely recommended as it does not impact upon treat-
ment paradigms. Although the authors address specific lymph
node basins to be resected as ‘first-echelon’ nodes, it must also
be acknowledged that the lymph node drainage of the liver is
quite variable. While certainly reasonable to perform a lympha-
denectomy, surgeons should understand that this procedure
only provides prognostic information that is not necessarily
actionable as there is no proven adjuvant therapy.
The authors appropriately point out the high rates of recur-
rence after a resection and the fact that the majority of
recurrences involve the liver. This is an important point as we
consider and study adjuvant strategies as well as the treatment
of recurrent liver disease. In the well-selected patient, a repeat
resection is reasonable to consider although unlikely to be
curative. We believe the future of adjuvant therapy for ICC, as
well as the treatment of recurrent liver disease, should involve
hepatic regional therapies. Intra-arterial therapies for ICC are
safe and can lead to stable disease or a partial response in up
to three-quarters of well-selected patients. Although the exist-
ing evidence is limited by the lack of prospective randomized
data, observational studies suggest an associated prolonged
overall survival. The most commonly used intra-arterial thera-
pies include transarterial chemoembolization (around 65% of
all intra-arterial therapies) and radioembolization with yttrium
90. Additionally, hepatic artery infusional chemotherapy
(HAIC) has been studied in patients with unresectable disease.
Single-arm studies of HAIC have demonstrated response rates
of approximately 50% and the potential for long-term sur-
vival.5 Given the promising response rates and survival associ-
ated with these therapies, further prospective evaluation within
clinical trials is warranted.
Lastly, the role of staging laparoscopy is reviewed and recom-
mended; at least selectively. Nobody would argue with the value
of avoiding a laparotomy in a patient with radiologically occult
unresectable disease. Although imaging is improving and the
yield of staging laparoscopy is likely decreasing, the selective use
of staging laparoscopy is well justified and should be considered
in high-risk cases and certainly in cases where the pre-operative
imaging raises specific concerns of metastatic disease.
We have much work to do to define better the extent and
role of surgery in the treatment of ICC. These carefully worded
consensus statements outline the issues well, and any investiga-
tor should be able to take away many issues for study. The def-
inition of resectability needs further refinement and the role of
surgery in patients with multifocal disease, or gross nodal dis-
ease needs better definition. Distinguishing between satellitosis
and multi-focal metastatic disease and whether these two enti-
ties are prognostically different requires further evaluation. A
routine lymphadenectomy has been recommended, but the
goals of this procedure require examination.
The controversy regarding the treatment of locally advanced
or metastatic cholangiocarcinoma has been put to rest with the
advent of gemcitabine plus cisplatin chemotherapy doublet as
a standard of care.6 This recent study showed an improved
overall survival for the combination compared with gemcita-
bine alone (11.7 versus 8.1 months, hazard ratio, 0.64,
P < 0.001), and thus the combination is now the standard of
care. This benefit held true in all subsets of different biliary
duct cancers including intrahepatic cholangiocarcinoma. One
of the unanswered controversies is the duration of therapy that
was limited to 24 weeks, or 8 cycles, in the ABC-02 study,6
while in practice oncologists may treat until progression or
intolerance occurs. The difference in outcome from that per-
spective has not been measured. If anything, there is greater
enthusiasm for developing therapy triads by adding biologics
of interest to the chemotherapy doublet. Despite solid scientific
rationales, such approaches have already failed when sorafenib
alone was added,7 with a similar fate for sorafenib combined
with erlotinib.8 Current studies evaluating other targets are
underway – with two focusing on MEK inhibition in combina-
tion with gemcitabine/cisplatin (http://www.clinicaltrials.gov
NCT01828034) and as a single agent (http://www.clinicaltrials.
gov NCT02042443). Genomic analyses of biliary cancers has
been reported by several groups; however, there is no clarity
yet regarding any specific patterns or clustering of genetic
changes. Nonetheless, mutation-driven studies are underway
despite the fact that their impact will be limited owing to the
low number of tumours expressing these genetic changes.
(http://www.clinicaltrials.gov NCT02073994, and NCT02150967).
There is significant controversy in the application of adjuvant
therapy for intrahepatic cholangiocarcinoma, and there still
lacks randomized phase III trials to help provide definitive rec-
ommendations. The best argument for the use of adjuvant che-
motherapy emanates from a meta-analysis of over 6000 patients
in 20 studies, most of which were retrospective.9 There was a
trend for adjuvant therapy over observation. However, this
lacked statistical significance (odds ratio 0.75, CI 0.55–1.01, P =
0.06). Added to the studies reported in the meta-analysis, a
recently completed single-arm phase II study of gemcitabine
plus capecitabine followed by capecitabine-based external-beam
radiotherapy showed promising safety and efficacy outcomes.10
The limitation of these studies, however, is the low number of
intrahepatic cholangiocarcinoma cases that were included. Thus,
there remains a strong need for future studies. In addition, there
is eager anticipation from three ongoing/recently-completed
studies: The BILCAP study evaluating capecitabine compared to
observation (http://www.clinicaltrials.gov NCT00363584), The
UNICANCER study of gemcitabine/oxaliplatin compared to
observation (http://www.clinicaltrials.gov NCT01313377) and
the BCAP study of gemcitabine compared to observation
(http://www.clinicaltrials.gov NCT000000820). Unfortunately,
these studies may have some of the same limitations of the oth-
ers – namely, low accrual of intrahepatic cholangiocarcinoma.
The rare situation of combined hepatocellular–cholan-
giocarcinoma (cHCC-CC) is well reviewed and discussed.
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Unfortunately, there is little to comment on as the disease is
rare and, therefore, difficult to study. There are limited data
on imaging, pathology and outcomes after resection of cHCC–
CC making significant conclusions impossible. For the patient
with a single resectable tumour, pre-operative diagnosis is
probably not important as the treatment is resection regardless
of final histology. For the patient with advanced disease, the
issue becomes more relevant. For the ICC component, there is
effective systemic chemotherapy6 and, for the HCC compo-
nent, there is effective regional therapy with intra-arterial
embolic therapies. Currently, we have imaging and tumour
markers to try to make the diagnosis and offer clues regarding
how therapy should proceed in patients who have cHCC–CC.
Needle biopsies are problematic as there is a significant chance
of a sampling error, as only a tiny percentage of the tumour is
sampled. Of course, whether HCC or ICC strategies are most
effective for advanced cHCC–CC is completely unknown.
Whether it is an atypical pattern of abnormal tumour markers,
imaging or biopsy that suggests cHCC–ICC, the best we have
to offer patients with this rare disease is an attempt at CC or
HCC treatment strategies – with the final decision probably
best discussed at a multi-disciplinary tumour board. The most
relevant issue for the practitioner is to be aware of the diagno-
sis and the potential treatment strategies available.
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